A short history of the science of small things. From Leeuwenhoek's lensgrinding in Delft to the Viking life-detection experiments on Mars; from Pasteur's swan-neck flask to the Human Microbiome Project; from Fleming's mould to the post-antibiotic future.
Microbes outnumber human cells in your body roughly one to one — the older 10:1 estimate has been revised down by Sender, Fuchs, and Milo (2016). Either way, you are about half microbe. The biosphere has always been their planet; we are recent guests.
Microbiology is the study of organisms too small to see with the unaided eye: bacteria, archaea, fungi, protists, and the borderline category of viruses. The field is younger than its objects by about three and a half billion years and younger than its founding observation by less than four centuries.
This deck covers the founding figures, the major taxonomic divisions, the great twentieth-century revolutions (germ theory, antibiotics, the discovery of the third domain), the microbiome era, the antibiotic-resistance crisis, and the open question of whether life exists or has existed beyond Earth.
Antonie van Leeuwenhoek (1632–1723), draper of Delft, autodidact, ground his own single-lens microscopes — small brass devices with a single bead-shaped glass, capable of magnification up to about 270x, more than any contemporary's instrument.
In a series of letters to the Royal Society beginning in 1673, he reported what he saw in pond water, in plaque from his own teeth, in semen, in the gut contents of fleas. The Royal Society's secretary Henry Oldenburg was sceptical until independent observers confirmed; Robert Hooke replicated the protozoa in 1677.
Leeuwenhoek had no formal training, no Latin, never published a book, and refused to sell his microscopes or reveal his lens-making technique. He called the things he saw animalcules. He had observed bacteria; the resolution was at the limit of what is possible with a single-lens design.
For approximately 150 years after his death, no one matched his observations. The compound microscope of the 1830s eventually surpassed his instruments — but until then, microbiology was effectively waiting.
Pasteur (1822–1895) is the closest the discipline has to a single founding figure. A trained chemist, he came to microbiology through the French wine and silkworm industries, and through the spontaneous-generation controversy.
The swan-neck flask experiment (1859) settled the question: nutrient broth in a flask whose neck had been drawn out into a long S-curve remained sterile indefinitely. The same broth in a broken-necked flask grew microbes within days. Microorganisms came from microorganisms; they did not arise spontaneously from non-living matter.
The other Pasteur achievements: pasteurisation (heating to selectively kill spoilage organisms without ruining wine or milk); the chicken-cholera attenuation work (1879) that established the principle of vaccines from weakened pathogens; and the rabies vaccine (first administered to nine-year-old Joseph Meister in 1885), the highest-stakes medical intervention of the nineteenth century.
The Pasteur Institute, founded in 1887 with public-subscription funding, is the institutional spine of French microbiology to this day.
Robert Koch (1843–1910), a country doctor in Wollstein who became Pasteur's German rival, completed the foundation. He developed the technical methods — solid culture media on potato slices and then on Petri's eponymous dishes (1887), the use of agar at his wife's suggestion, methylene blue staining — that allowed pure cultures of single bacterial species.
The breakthrough discoveries: anthrax, Bacillus anthracis (1876) — the first time a specific bacterium was definitively shown to cause a specific disease. Tuberculosis, Mycobacterium tuberculosis (1882) — at the time the cause of one in seven human deaths in Europe. Cholera, Vibrio cholerae (1883) — settling a long-running argument that John Snow's epidemiology had won but that the medical establishment had not yet conceded.
Koch was awarded the 1905 Nobel Prize. The germ theory of disease was, by then, no longer disputable. The transformation of nineteenth-century medicine that followed — sanitation, antiseptic surgery, vaccines, eventually antibiotics — is the most consequential application of any biological discovery.
The criteria Koch laid out for establishing that a particular microorganism causes a particular disease, formalised in 1890. They have been refined since — viruses break the second; obligate human pathogens the third; asymptomatic carriers the first — but the framework remains the basis of medical microbiology.
The microorganism must be present in all individuals with the disease, and absent in healthy individuals.
The microorganism must be isolable from a diseased individual and grown in pure culture outside the host.
The cultured microorganism must, when introduced into a healthy susceptible host, cause the same disease.
The microorganism must be re-isolated from the experimentally infected host and shown to be identical to the original.
Microbial nomenclature follows Linnaean binomials — genus and species — but with a culture and a rule-set distinct from animal and plant taxonomy. Names are governed by the International Code of Nomenclature of Prokaryotes; valid publication requires deposition of a type strain in two recognised culture collections in different countries.
The names tell stories. Escherichia coli — Theodor Escherich, who described it in 1885; coli for the colon. Yersinia pestis — Alexandre Yersin, the bacterium of plague. Salmonella — Daniel Salmon, the American veterinarian. Shigella — Kiyoshi Shiga, the dysentery bacterium.
The renaming pace is brisk. Pneumocystis carinii, long thought a protozoan, was reclassified as a fungus and renamed Pneumocystis jirovecii for human cases. The Bergey's Manual lineage and now the List of Prokaryotic names with Standing in Nomenclature (LPSN) are the authoritative references.
The most-studied microorganisms. Single-celled, prokaryotic (no nucleus), with a peptidoglycan cell wall, dividing by binary fission. About 30,000 named species; current best estimates put total bacterial diversity in the millions.
The Gram stain (Hans Christian Gram, 1884) divides them by cell-wall structure. Gram-positive bacteria — thick peptidoglycan, retain crystal violet, stain purple. Includes Staphylococcus, Streptococcus, Bacillus, Clostridium. Gram-negative bacteria — thin peptidoglycan, outer lipopolysaccharide membrane, stain pink. Includes E. coli, Salmonella, Pseudomonas, Helicobacter.
The distinction matters clinically. Gram-negative bacteria's outer membrane makes them harder to kill and the LPS endotoxin component drives much of the systemic damage of Gram-negative sepsis. Antibiotic spectra are routinely described in Gram-positive vs Gram-negative terms.
Beyond pathogens: nitrogen-fixing rhizobia, soil saprotrophs, marine cyanobacteria (which produce roughly half the planet's oxygen), the symbionts in deep-sea hydrothermal vent communities. Disease bacteria are a small minority; the dominant role of bacteria is biogeochemical.
Until the late 1970s, life was divided into prokaryotes (bacteria) and eukaryotes (everything else with a nucleus). Carl Woese at the University of Illinois, working with George Fox, used 16S ribosomal RNA sequence comparison to redraw the tree.
The 1977 paper showed that the methanogens — methane-producing organisms found in cow rumens, swamp sediment, and hot springs — were as different from ordinary bacteria as bacteria were from eukaryotes. Woese proposed a third domain, eventually called Archaea.
The three-domain tree (Bacteria, Archaea, Eukarya) was resisted for fifteen years and is now textbook. The eukaryotic cell is now understood to have arisen from an archaeal host (probably an Asgard archaean, lineage discovered in 2015) that engulfed a bacterium that became the mitochondrion.
Archaea inhabit extreme environments more often than bacteria do — boiling acidic hot springs, hypersaline lakes, anoxic sediments — but are also abundant in soil, the open ocean, and the human gut. Methanobrevibacter smithii in your colon makes the methane in your flatulence.
Viruses sit on the boundary of life. They are obligate intracellular parasites that consist of a nucleic acid genome (DNA or RNA) packaged in a protein capsid, sometimes with a lipid envelope. They cannot reproduce, metabolise, or maintain themselves without a host cell.
Whether to call them alive is genuinely unsettled. They evolve. They have genes. They are subject to natural selection. They lack independent metabolism, energy production, and replication machinery. The standard textbook position — they are not alive — has been actively challenged by the discovery of giant viruses (mimivirus, pandoravirus) with genomes larger than some bacteria and with metabolic genes previously thought viral organisms lacked.
Either way, viruses are the most abundant biological entities on Earth — about 10^31 viral particles, ten times the number of bacterial cells. They are a major force in marine ecology (lysing roughly 20% of ocean bacteria daily), in microbial gene transfer, and in human disease.
The bacteriophages — viruses that infect bacteria — are now of clinical interest as antibiotic alternatives in resistant infections.
Fungi are eukaryotic, with cell walls of chitin (not cellulose, as in plants). The kingdom includes microscopic forms — the yeasts, the moulds — and macroscopic ones (mushrooms, but their fruiting bodies are only the small visible part of much larger underground mycelial networks).
Microbiologically important fungi: Saccharomyces cerevisiae (baker's and brewer's yeast — the eukaryotic model organism, the first eukaryote whose genome was fully sequenced, 1996); Candida albicans (the opportunistic pathogen behind thrush and bloodstream infections); Penicillium (the genus that gave Fleming penicillin); Aspergillus (food-spoilage and respiratory infection); the dermatophytes (athlete's foot, ringworm).
The estimated number of fungal species is between 2 and 4 million; only about 150,000 have been described. They are critical decomposers — without fungi, terrestrial carbon cycles do not close — and crucial plant symbionts through the mycorrhizal associations that connect 90%+ of land plants to soil networks.
The post-2017 work on Cryptococcus antifungal resistance and the rise of Candida auris (first described 2009) have made fungal infections a serious clinical concern, especially in immunocompromised populations.
Protists are the heterogeneous group of eukaryotic microorganisms that are neither plants, animals, nor fungi. The category is paraphyletic — i.e., not a single evolutionary lineage — and exists mostly because the alternatives are worse.
The major lineages: excavates (including the parasites Giardia and Trypanosoma); SAR clade — Stramenopiles, Alveolates, Rhizaria (diatoms, dinoflagellates, the malaria parasite Plasmodium, the foraminifera); amoebozoans (most amoebae, including the brain-eating Naegleria fowleri); archaeplastida (which includes the green algae and, by descent, the entire plant kingdom).
The pathogens that matter clinically: Plasmodium falciparum (malaria, ~600,000 deaths per year), Trypanosoma brucei (sleeping sickness), Trypanosoma cruzi (Chagas disease), Toxoplasma gondii (toxoplasmosis, with the strange behavioural-modification literature in rodents), Entamoeba histolytica (amoebic dysentery).
The marine plankton — diatoms, dinoflagellates, coccolithophores — are protists that drive most ocean primary production and a substantial fraction of global oxygen production.
Microbial mats are layered, sheet-like communities of microorganisms that grow on solid surfaces in shallow water. The visible analogue today: the Shark Bay stromatolites in Western Australia, where cyanobacterial mats accrete carbonate sediments into laminated structures.
Stromatolites are the oldest unambiguous fossil evidence of life. Lithified microbial mats from the Pilbara Craton in Western Australia and Strelley Pool in Greenland date to about 3.48 billion years ago. For roughly the first two and a half billion years of Earth history, microbial mats were the dominant macroscopic feature of shallow marine environments.
The Great Oxidation Event (~2.4 billion years ago), when atmospheric oxygen first rose to appreciable levels, was driven by photosynthesising cyanobacteria in mats producing oxygen at a rate that overwhelmed the planet's reducing chemistry. The atmosphere we breathe is the metabolic exhaust of microbes from before any animal existed.
Microbes have been found growing in conditions previously thought beyond the limits of life. The categories: thermophiles (high temperature; up to 122°C for Methanopyrus kandleri at hydrothermal vents); psychrophiles (low temperature; growth at -20°C in Antarctic brine channels); halophiles (high salt; Haloferax and Halobacterium in saturated brines); acidophiles (down to pH 0; Picrophilus); alkaliphiles (up to pH 11+); piezophiles (high pressure; the Mariana Trench).
Radiation resistance: Deinococcus radiodurans survives doses of ionising radiation 1,000× lethal to humans, by maintaining multiple genome copies and an unusually efficient DNA-repair system. The Tardigrade of the popular literature is a tiny animal, not a microbe, but it parallels the strategy.
Extremophiles have practical importance: their proteins (notably enzymes) tolerate conditions that disable normal proteins, and so are valuable in industrial applications. The most famous case is Taq polymerase, the next page.
Thomas Brock, microbiologist at Indiana University, spent the 1960s sampling the hot springs of Yellowstone National Park. In 1969, with his student Hudson Freeze, he isolated a thermophilic bacterium from Mushroom Pool that grew at 70°C. He named it Thermus aquaticus.
The bacterium was deposited in the American Type Culture Collection. For fifteen years, nothing came of it commercially. Then Kary Mullis at Cetus Corporation, in 1983, conceived the polymerase chain reaction. The original PCR procedure required adding fresh DNA polymerase at each cycle because the enzyme was destroyed by the high-temperature denaturation step.
The 1986 insight: use a thermostable polymerase. T. aquaticus's DNA polymerase — soon known as Taq polymerase — survived 95°C and made automated PCR possible. The molecular biology revolution of the 1990s, the Human Genome Project, modern forensics, and COVID PCR testing all rest on a bacterium fished out of a Yellowstone hot spring by a curious scientist who was studying it for its own sake.
Brock's case is the textbook argument for basic, undirected science. The royalties Cetus and Roche received from Taq exceed many billions of dollars. Brock received nothing.
The collection of microorganisms living on and in a multicellular host. The term came into wide use after Joshua Lederberg's 2001 essay; the science exploded over the following two decades as 16S rRNA sequencing made it possible to inventory community composition without culturing organisms most of which can't be cultured.
Compositional findings: the human gut holds 100 trillion microbes, dominated by the phyla Bacteroidetes and Firmicutes. The mouth, skin, vagina, and gut each have characteristic communities. Most of the body's microbial mass is in the colon.
Functional findings: the gut microbiome ferments fibre into short-chain fatty acids that feed the colonocytes; synthesises vitamins (K, several B vitamins); educates the immune system in early life; influences drug metabolism. Disturbed microbiomes have been associated — sometimes correlatively, sometimes causally — with inflammatory bowel disease, obesity, diabetes, allergies, autism, depression. The strength of the causal evidence varies by case.
The skin and oral microbiomes are less studied but increasingly recognised: the acne literature, the periodontitis literature, the case for keystone species in oral biofilms.
The Human Microbiome Project — launched 2008 by the US National Institutes of Health, $115 million in initial funding, parallel European MetaHIT consortium — was the first systematic survey of the human-associated microbial ecosystem.
Phase 1 (2008–2012) sampled 242 healthy adults at five major body sites (mouth, skin, nose, vagina, gut) and produced reference 16S rRNA inventories. The 2012 publications in Nature and Nature Biotechnology described unexpectedly high inter-individual variation in taxonomic composition but striking convergence at the level of metabolic function.
Phase 2, the integrative HMP (2014–2019), studied disease-relevant cohorts: pregnancy and preterm birth, IBD, type-2 diabetes. Findings have been mixed; many of the early "the microbiome causes disease X" claims have not survived rigorous prospective study.
The current state: microbiome differences are real and reproducible; the causal direction in disease is much harder to establish than early enthusiasm assumed. Personalised microbiome diagnostics remain mostly aspirational. Faecal microbiota transplantation for C. difficile is the one well-validated therapeutic application.
Fecal microbiota transplantation (FMT) is the transfer of stool from a healthy donor into a recipient's gastrointestinal tract. The intuition is old (fourth-century Chinese medicine described "yellow soup"); the modern protocol was formalised in the 1950s for refractory Clostridioides difficile infection.
The pivotal randomised trial — Els van Nood et al., NEJM, January 2013 — was stopped early for efficacy. FMT cured 81% of recurrent C. difficile patients vs 31% with vancomycin. The result was decisive enough to change clinical guidelines globally and to launch an industry.
FMT is now the standard of care for recurrent C. difficile. Trials for ulcerative colitis, Crohn's disease, irritable bowel syndrome, obesity, autism, and cancer immunotherapy response have produced mixed results — promising in some, null in others.
The regulatory framework remains awkward: the FDA treats FMT as an investigational drug. The 2022 approval of Rebyota (a microbiome-based therapy for C. diff) and the 2023 approval of Vowst (an oral capsule formulation) are the first commercial products.
Alexander Fleming returned from holiday to his St Mary's lab in September 1928, found a contaminated Staphylococcus plate, observed that the contaminating Penicillium notatum mould had created a bacterial-clearance zone around itself, and recognised what he was looking at. The publication in 1929 was largely ignored.
The development into a clinical drug was the 1939–41 Oxford project of Howard Florey and Ernst Chain, with Norman Heatley solving the production scale-up. The first patient — Albert Alexander, an Oxford policeman with a streptococcal infection from a rose-bush scratch — was treated in 1941; he initially recovered but the supply ran out and he died. By 1944, US wartime production was supplying enough penicillin for the D-Day invasion.
Selman Waksman at Rutgers led the soil-actinomycete screening program that produced streptomycin (1943, the first effective TB drug, isolated by graduate student Albert Schatz), neomycin, and several others. Waksman coined the word "antibiotic." The Schatz-Waksman dispute over credit for streptomycin is a useful cautionary case study in scientific authorship.
By 1960 the major classes — beta-lactams, aminoglycosides, tetracyclines, macrolides, glycopeptides — had been discovered. Almost nothing fundamentally new since.
Resistance is older than the antibiotic era. Bacteria evolved antibiotic-production and antibiotic-resistance capabilities over billions of years of microbial competition. Soil bacteria carry resistance genes against drugs they have never seen; resistance is in the metagenomic baseline of any environment one looks at.
Clinical resistance has tracked clinical use. Penicillin resistance in Staphylococcus aureus appeared within a few years of clinical introduction in the 1940s. MRSA (methicillin-resistant S. aureus) first identified 1961, the year after methicillin's introduction. VRE, XDR-TB, NDM-1-carrying Gram-negatives, the carbapenem-resistant Enterobacteriaceae — each new resistance front has followed each new drug.
The 2019 Lancet study estimated 4.95 million deaths globally associated with bacterial antimicrobial resistance, of which 1.27 million were directly attributable. This already exceeds the death toll of malaria or HIV.
The pipeline problem: pharmaceutical companies have largely exited antibiotic R&D — the economics are bad (a successful drug should be used sparingly, which destroys the revenue model). The post-antibiotic era is not a forecast; it is, for some infections in some places, already here.
The phrase, often attributed to former WHO director-general Margaret Chan in a 2012 speech, is a real possibility. A world in which routine surgery becomes high-risk because perioperative infection cannot be reliably treated; in which chemotherapy regimens that depend on managing neutropenic infection become unviable; in which simple skin infections again kill.
The mitigation strategies are well-known and difficult: antibiotic stewardship (use them less, more selectively), infection control (hand hygiene, vaccination, water and sanitation), agricultural reform (eliminate prophylactic antibiotics in livestock, which still account for a majority of global antibiotic use by mass), diagnostic improvement (rapid pathogen identification reduces empirical broad-spectrum prescribing), and new therapeutic modalities.
The new modalities under active research: bacteriophage therapy (using viruses that infect bacteria, with case reports of compassionate use in resistant infections); monoclonal antibodies against specific pathogens; antimicrobial peptides; CRISPR-based antimicrobials; microbiome restoration.
None of these has yet displaced antibiotics for general clinical use. The most likely future is: stewardship plus new drugs plus phage plus targeted approaches plus loss of treatability for some pathogens.
Microbial fermentation is the production technology behind a long list of useful molecules. Antibiotics (penicillin from Penicillium, streptomycin from Streptomyces); insulin (since 1982 produced in E. coli bearing the human gene); growth hormone; the recombinant clotting factors; many therapeutic monoclonal antibodies (in CHO cells, technically eukaryotic, but the principle is the same).
Vaccines: traditional vaccine production grows the pathogen (or an attenuated relative) at scale, then inactivates or extracts the antigen. Modern subunit and recombinant vaccines (the hepatitis B surface antigen, the HPV virus-like particles) are produced by yeast or bacterial fermentation.
The mRNA vaccines that broke through during the COVID pandemic represented a different paradigm — produced not by growing organisms but by enzymatic synthesis in a cell-free system — but the lipid-nanoparticle delivery and the mass production owe much to the fermentation engineering tradition.
And the food: yogurt (Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus), cheese (varied lactic acid bacteria and the moulds Penicillium roqueforti and Penicillium camemberti), bread, beer, wine, sauerkraut, kimchi, miso, tempeh, soy sauce, vinegar, kombucha. Every cuisine on Earth uses microbial fermentation; most users never think of it as microbiology.
A handful of pathogens shape the global mortality picture.
Tuberculosis — Mycobacterium tuberculosis. ~1.3 million deaths per year as of the mid-2020s; the leading single-pathogen killer, restored to that position post-COVID. Slow-growing, intracellular, requires multi-drug regimens of 6+ months. MDR-TB and XDR-TB are growing problems.
Malaria — Plasmodium falciparum dominates mortality. ~600,000 deaths per year, mostly children under five in sub-Saharan Africa. The RTS,S vaccine (rolled out from 2021) and R21 (2023) are the first malaria vaccines; modest efficacy is expected to translate to substantial population impact.
HIV — retrovirus, ~600,000 deaths per year, much reduced from the 2 million-plus peak in the early 2000s thanks to antiretroviral therapy. Long-acting injectables and the prospect of a cure (WHO tracks the case literature) are active fronts.
Influenza — RNA virus, seasonally killing 290,000 to 650,000 globally per WHO estimates. The H5N1 avian strain is the recurrent pandemic-preparedness concern; H1N1 in 2009 was the most recent declared influenza pandemic.
SARS-CoV-2 emerged in late 2019 and went pandemic by March 2020. The official WHO global death toll exceeds 7 million; excess-mortality estimates are double that. The pandemic was the largest infectious-disease event since 1918.
The preparedness lessons partially absorbed: surveillance must be genomic and real-time (the COG-UK and GISAID consortia matured during the pandemic and now provide near-real-time variant tracking); diagnostic tests must be deployable within weeks; vaccine platforms (mRNA, viral vector) must be ready to be retargeted; therapeutics and supply chains for them must be at standing capacity.
The lessons partially un-learned: pandemic preparedness funding has fallen since the acute-phase peak; the political will for serious investment evaporates between events; trust in public-health institutions is, in many countries, lower than before the pandemic.
The microbiologists' working assumption: another pandemic-scale respiratory event is a question of when, not if. The candidate pathogens monitored most closely are influenza A subtypes (especially H5N1 in dairy cattle as of 2024–25), coronaviruses in bats, and the constellation of emerging zoonoses tracked by the WHO R&D Blueprint priority list.
Synthetic biology builds on microbiology by treating microorganisms as programmable platforms. The major successes are mostly fermentation-based.
Artemisinin: the antimalarial precursor, traditionally extracted from sweet wormwood. Jay Keasling's group at Berkeley engineered yeast (Saccharomyces cerevisiae) to produce artemisinic acid via twelve heterologous enzymatic steps. The Nature paper appeared in 2013; Sanofi licensed the process for production at scale.
Insulin in E. coli (Genentech, 1978–1982) is the foundational case — the first commercial product of recombinant DNA technology, and the model for almost everything since.
Spider silk, shark squalene, cocoa flavonoids, cannabinoids: an expanding list of secondary metabolites and high-value molecules produced in engineered microbes.
The frontier work — Craig Venter's synthetic Mycoplasma mycoides JCVI-syn1.0 (2010), the syn3.0 minimal cell (2016), the ongoing engineering of yeast chromosomes (the Sc2.0 consortium) — extends what "microbe as platform" can mean.
The use of microorganisms to clean up environmental pollution. The basic principle: microbes have, somewhere in their collective metabolic repertoire, the enzymes to degrade most organic compounds, including many synthetic ones.
The major successes: oil-spill remediation (the Exxon Valdez 1989 cleanup used naturally occurring oil-degrading bacteria stimulated by added nutrients, with mixed results; the Deepwater Horizon 2010 spill saw rapid microbial degradation of much of the released hydrocarbons). Solvent contamination (Dehalococcoides bacteria reduce chlorinated solvents at contaminated sites). Heavy-metal sequestration in mining-waste impoundments.
Plastic biodegradation is the active research frontier: Ideonella sakaiensis 201-F6, isolated in 2016 from a Japanese recycling plant, secretes PETase and MHETase enzymes that degrade PET plastic. Engineered variants of these enzymes work much faster; commercial deployment for bottle-grade PET is reaching pilot scale.
Bioremediation is generally slower than chemical remediation but cheaper and gentler. It is rarely a complete solution alone; in combination with physical containment and chemical treatment, it has become standard practice.
The largest single ecosystem on Earth lies underground. Microbial life inhabits sediments and rock kilometres below the seafloor and the continental crust, fed by chemical energy from rock-water reactions rather than photosynthesis.
The discovery developed through the 1990s and 2000s as scientific drilling programs (the Ocean Drilling Program, IODP, and the Deep Carbon Observatory's Census of Deep Life initiative) returned cores from increasing depths. Cells per gram of subsurface sediment are low — 10^4 to 10^7 — but the volume is vast.
Current best estimates: deep-subsurface microbial biomass is comparable to all surface biomass combined. The cells turn over very slowly — generation times are estimated in centuries to millennia — and live close to the metabolic limit of life.
Why this matters beyond curiosity: the deep biosphere is a major reservoir for carbon and nitrogen cycling on geologic timescales; it bears on the question of where life arose (the deep, hot, mineral-rich subsurface is one of the favoured candidate origin environments); and it is the closest terrestrial analogue for what life might look like on Mars or beneath Europa.
The Viking landers, July and September 1976, carried four life-detection experiments. Three returned ambiguous or negative results. The fourth — Gilbert Levin's Labeled Release experiment — added 14C-labelled nutrient to a soil sample and detected radioactive gas release consistent with microbial metabolism. A control sample heated to sterilising temperatures gave no signal.
The Viking team concluded the result was probably abiotic chemistry, in part because the companion gas-chromatograph-mass-spectrometer (GCMS) found no organic molecules. Levin disagreed for the rest of his life and continued to argue Viking had detected Martian life. The 2008 Phoenix lander's discovery of perchlorates in Martian soil — which would degrade organics in the GCMS heating step — has reopened the case but not settled it.
Curiosity (2012–) and Perseverance (2021–) have found organic molecules, methane fluctuations whose source remains debated, and habitable-environment evidence (former lake beds, neutral-pH water). None has been a life-detection mission per se. The Perseverance sample-return mission, if it returns samples to Earth, will be the highest-stakes microbiology experiment in history.
The persistent question: are we alone? The microbial-biology answer remains: we don't know, but the closer we look the more habitable Mars appears to have once been.
↑ The hidden world of microbiomes
Watch · gut microbiome explained
Watch · FRONTLINE · when antibiotics don't work
Ed Yong's I Contain Multitudes remains the best single popular introduction to the microbiome era. For technical depth, Brock Biology of Microorganisms (Madigan, Bender, Buckley) is the standard textbook. Carl Zimmer's A Planet of Viruses for viruses; Maryn McKenna for the antibiotic-resistance literature.
Microbes built the atmosphere, run the geochemical cycles, and constitute most of the biomass and most of the genetic diversity on Earth. They also kill most of the children, in most of human history, who have died.
The twentieth-century microbiological revolution — germ theory, antibiotics, vaccines, sanitation — extended human life expectancy by roughly thirty years on average. The twenty-first-century revolution may be of the same scale. We are early in understanding what the microbiome does, what synthetic biology will let us build, and what the next pandemic will require.
The unsolved problems are large and concrete: rebuild the antibiotic pipeline; deliver tuberculosis and malaria interventions at scale; understand the gut–brain axis well enough to know whether the microbiome causes mood disorders or merely reflects them; settle the Mars question. None of these is conceptually unreachable; all of them are organisationally hard.
The science is, by reasonable estimate, the youngest fundamental field still going. Most of what is known has been learned since 1850. Most of what will be known has not been learned yet.
Microbiology — Volume V, Deck 13 of The Deck Catalog. Set in Inter and JetBrains Mono. Off-white #f5f5f0; petri-dish green and laboratory plum accents.
Thirty-two leaves on the science of small things. Microbes ran the planet for three and a half billion years before us; they will run it for whatever comes after.
↑ Vol. V · Nature · Deck 13